An analyst at Citizens JMP, Jason Butler, has adjusted the price target for Dynavax (DVAX, Financial), lowering it from $33 to $31. Despite this reduction, the firm maintains an Outperform rating on the stock. Dynavax has announced exceptional growth in its HEPLISAV-B sales, achieving a 36% increase compared to the previous year. The product now captures a 43% share of the market, a rise of 2%. Looking ahead, Dynavax aims to reach the upper range of its HEPLISAV-B sales guidance, between $305 million and $325 million, by the end of 2025.
Furthermore, Dynavax is expanding its pipeline with new programs, including a trial for an H5N1 flu vaccine expected to commence this year. Additionally, the company plans to enter the clinic with a Lyme disease program by 2027.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Dynavax Technologies Corp (DVAX, Financial) is $24.00 with a high estimate of $33.00 and a low estimate of $10.00. The average target implies an upside of 119.78% from the current price of $10.92. More detailed estimate data can be found on the Dynavax Technologies Corp (DVAX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Dynavax Technologies Corp's (DVAX, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Dynavax Technologies Corp (DVAX, Financial) in one year is $12.13, suggesting a upside of 11.08% from the current price of $10.92. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Dynavax Technologies Corp (DVAX) Summary page.
DVAX Key Business Developments
Release Date: May 06, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Dynavax Technologies Corp (DVAX, Financial) reported its highest ever first quarter net revenue for HAMB of $65 million, a 36% increase compared to the previous year.
- The company is on track to achieve the top half of its full-year guidance range for net product sales, projected between $305 to $325 million.
- Dynavax is advancing its development pipeline with key clinical trial milestones for shingles and plague vaccine programs, and new programs in pandemic influenza and Lyme disease.
- The company's shingles vaccine program shows promise with comparable immunogenicity and improved tolerability compared to existing market leaders.
- Dynavax has executed over 85% of its $200 million share repurchase program, demonstrating a disciplined approach to capital allocation and shareholder value.
Negative Points
- The company recorded a GAAP net loss of $96 million for the first quarter of 2025, primarily due to the GAAP accounting treatment of debt refinancing.
- R&D expenses increased to $19 million in the first quarter, up from $14 million the previous year, with expectations for further increases.
- SG&A expenses rose to $48 million, partly due to incremental proxy-related expenses.
- An allowance for doubtful accounts of $11 million was recorded due to heightened credit risks from Clover Biopharmaceuticals.
- The company faces uncertainties in the regulatory environment, particularly with potential changes in FDA requirements for vaccine trials.
